5-cyclopropyl-3-phenyl-1H-pyrazole | 1208127-10-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-cyclopropyl-3-phenyl-1H-pyrazole
• 英文别名: 3-cyclopropyl-5-phenyl-1H-pyrazole
• CAS: 1208127-10-9
• 化学式: C₁₂H₁₂N₂
• 分子量: 184.241
• InChiKey: CNRDFXGNMQIYND-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  28.7
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  5-cyclopropyl-3-phenyl-1H-pyrazole 在 碘 、 potassium carbonate 、 sodium iodide 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 2.0h， 生成 5-cyclopropyl-4-iodo-3-phenyl-1H-pyrazole
  参考文献：
  名称：

  [EN] PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
  [FR] DÉRIVÉS D'ACIDE CARBONIQUE SUBSTITUÉS PAR PYRAZOLYLE EN TANT QUE MODULATEURS DU RÉCEPTEUR DE LA PROSTACYCLINE PGI2 ADAPTÉS AU TRAITEMENT DE TROUBLES LE FAISANT INTERVENIR

  摘要：

  Formula Ia的吡唑衍生物及其药物组成物，可调节PGI2受体的活性。本发明的化合物和药物组成物用于治疗以下疾病：肺动脉高压（PAH）及相关疾病；血小板聚集；冠状动脉疾病；心肌梗死；短暂性缺血性发作；心绞痛；中风；缺血再灌注损伤；再狭窄；心房颤动；血栓形成在冠状动脉成形术或冠状动脉旁路手术个体中或在患有心房颤动的个体中；动脉粥样硬化；动脉粥样血栓形成；哮喘或其症状；糖尿病相关疾病，如糖尿病周围神经病变、糖尿病肾病或糖尿病视网膜病变；青光眼或其他眼睛异常眼压疾病；高血压；炎症；牛皮癣；银屑病性关节炎；类风湿性关节炎；克罗恩病；移植排斥；多发性硬化症；系统性红斑狼疮（SLE）；溃疡性结肠炎；缺血再灌注损伤；再狭窄；动脉粥样硬化；痤疮；1型糖尿病；2型糖尿病；败血症；慢性阻塞性肺疾病（COPD）。

  公开号：

  WO2010068242A1
• 作为产物：
  描述：

  1-cyclopropyl-3-phenylpropane-1,3-dione 在 hydrazine hydrate 、 溶剂黄146 作用下， 以 乙醇 为溶剂， 反应 0.83h， 以85%的产率得到5-cyclopropyl-3-phenyl-1H-pyrazole
  参考文献：
  名称：

  [EN] PIKFYVE KINASE INHIBITORS
  [FR] INHIBITEURS DE KINASE PIKFYVE

  摘要：

  本发明涉及作为磷脂酰肌醇-3-磷酸5-激酶（PIKfyve）抑制剂的化合物，以及它们用于治疗与PIKfyve相关的疾病和紊乱的用途。

  公开号：

  WO2021163727A1

文献信息

• Chemoselective synthesis of substituted pyrazoles through AgOTf-catalyzed cascade propargylic substitution–cyclization–aromatization
  作者：Su-Xia Xu、Lu Hao、Tao Wang、Zong-Cang Ding、Zhuang-Ping Zhan

  DOI：10.1039/c2ob27016a

  日期：——

  A cascade AgOTf-catalyzed chemoselective approach to 3,5/1,3-disubstitued pyrazoles from propargylic alcohols and para-tolylsulfonohydrazide has been developed. Good chemoselectivity is observed depending on the different substituents in the alkyne moiety of the propargylic alcohols, generating two different kinds of products through different aromatization mechanisms. The pyrazolo[5,1-a]isoquinoline skeleton can also be effectively constructed by this method through a cascade bicyclization process.

  开发了一种瀑布式AgOTf催化的化学选择性方法，能够从丙炔醇和对甲苯磺酰肼得到3,5/1,3二取代的吡唑。根据丙炔醇中炔烃部分的不同取代基，观察到良好的化学选择性，通过不同的芳构化机制生成两种不同类型的产物。该方法还可以通过级联双环化过程有效构建吡唑[5,1-a]异喹啉骨架。
• Multi-Step Synthesis by Using Modular Flow Reactors: The Preparation of YneOnes and Their Use in Heterocycle Synthesis
  作者：Ian R. Baxendale、Søren C. Schou、Jörg Sedelmeier、Steven V. Ley

  DOI：10.1002/chem.200902906

  日期：2010.1.4

  Multi‐step in flow: The palladium‐catalysed acylation of terminal alkynes for the synthesis of yneones as well as their further transformation to various heterocycles in a continuous‐flow mode is presented. Furthermore, an extension of the simple flow configuration that allows for easy batch splitting and the generation of a heterocyclic library is described (see scheme).

  多步骤中流动：末端炔烃的为炔的合成中钯催化酰化那些以及它们进一步转化为各种杂环在连续流动模式被呈现。此外，描述了简单流配置的扩展，该扩展允许简单的批拆分和杂环库的生成（请参阅方案）。
• PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
  申请人：Tran Thuy-Anh

  公开号：US20110224262A1

  公开（公告）日：2011-09-15

  Pyrazole derivatives of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (COPD).

  公式Ia的吡唑衍生物及其制药组合物，用于调节PGI2受体的活性。本发明的化合物和制药组合物用于治疗以下疾病的有用方法：肺动脉高压（PAH）及相关疾病；血小板聚集；冠状动脉疾病；心肌梗死；短暂性脑缺血发作；心绞痛；中风；缺血再灌注损伤；再狭窄；房颤的血栓形成或在患有房颤的个体中的冠状动脉成形术或冠状动脉旁路手术；动脉粥样硬化；动脉粥样血栓形成；哮喘或其症状；与糖尿病相关的疾病，如糖尿病周围神经病、糖尿病肾病或糖尿病视网膜病变；青光眼或其他眼部异常眼压的疾病；高血压；炎症；牛皮癣；银屑病性关节炎；类风湿性关节炎；克罗恩病；移植排斥；多发性硬化症；系统性红斑狼疮（SLE）；溃疡性结肠炎；再灌注损伤；再狭窄；动脉粥样硬化；痤疮；1型糖尿病；2型糖尿病；败血症；慢性阻塞性肺疾病（COPD）。
• Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto
  申请人：Arena Pharmaceuticals, Inc.

  公开号：US09012478B2

  公开（公告）日：2015-04-21

  Pyrazole derivatives of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (COPD).

  公式Ia的吡唑衍生物及其药物组成物可以调节PGI2受体的活性。本发明的化合物和药物组成物适用于以下治疗方法：肺动脉高压（PAH）及相关疾病；血小板聚集；冠状动脉疾病；心肌梗塞；短暂性脑缺血发作；心绞痛；中风；缺血再灌注损伤；再狭窄；房颤；血栓形成在血管成形术或冠状动脉旁路手术患者或患有房颤的个体中；动脉粥样硬化；动脉粥样硬化性血栓形成；哮喘或其症状；糖尿病相关疾病，如糖尿病周围神经病、糖尿病肾病或糖尿病视网膜病变；青光眼或其他眼部异常眼压疾病；高血压；炎症；银屑病；银屑病性关节炎；类风湿性关节炎；克罗恩病；移植排斥反应；多发性硬化症；系统性红斑狼疮（SLE）；溃疡性结肠炎；缺血再灌注损伤；再狭窄；动脉粥样硬化；痤疮；1型糖尿病；2型糖尿病；败血症；慢性阻塞性肺疾病（COPD）。
• Synthesis of Pyrazoles through Copper-Catalyzed Three-Component Coupling of Aldehydes, Alkynes, and p-Toluenesulfonylhydrazide
  作者：Zhuang-ping Zhan、Feng Wu、Lu Hao

  DOI：10.3987/com-12-12646

  日期：——

  A convenient one-pot synthesis of 3,5-disubstitued 1H-pyrazoles through copper-catalyzed three-component coupling of aldehydes, alkynes, and p-toluenesulfonylhydrazide has been developed. This method provides a flexible and rapid route to 3,5-disubstituted 1H-pyrazoles.